Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115509) titled 'A Phase II Study of Iparomlimab and Tuvonralimab(PD-1/CTLA-4 Bispecific Antibody)Plus Tofacitinib in Patients With Immunotherapy-Refractory Advanced Esophageal Squamous Cell Carcinoma' on Dec. 26, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shandong Provincial Hospital Affiliated to Shandong First Medical University
Condition:
Esophageal Squamous Cell Carcinoma
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2025-12-26
Target Sample Size: Experimental group:26;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/sh...